Invagen Pharmaceuticals Inc., a wholly owned subsidiary of Cipla, has entered into a strategic partnership with Qilu Pharmaceutical for the exclusive licensing and supply of QL2107, a biosimilar to pembrolizumab (Keytruda), for the US market.

Under the agreement, Qilu Pharmaceutical will be responsible for the product’s development, regulatory registration and supply, while Cipla USA Inc. will lead its commercialisation in the US, leveraging Cipla’s established commercial capabilities.

The partnership strengthens Cipla’s strategy to expand its biosimilar and oncology portfolio while supporting broader access to advanced biologic treatments at potentially lower costs.

Achin Gupta, Managing Director and Global Chief Executive Officer, Cipla, said the collaboration combines Qilu’s development capabilities with Cipla’s commercial presence to expand access to high-quality biologics for patients.

Marc Falkin, Chief Executive Officer, Cipla North America, said QL2107 will support the company’s plans to expand its biosimilar portfolio and is positioned for a potential US launch following regulatory approval.

Qilu Pharmaceutical said the partnership combines its R&D and manufacturing capabilities with Cipla’s US commercial expertise to support the availability of an affordable pembrolizumab biosimilar for American patients.